TTFields has been approved by the FDA for the treatment of patients with glioblastoma multiforme. However, the clinical effect and safety of radiotherapy concurrent of TTFields is not definite. In this study, the investigators conduct a phase II clinical trial to evaluate the efficacy and safety of this strategy.
the investigators plan to recruit 30 patients to evaluate the efficacy and safety of this strategy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
The TTFields, consisting of low-intensity, 200 kHz frequency, alternating electric fields, was delivered (≥ 18 hours/d) via 4 transducer arrays on the shaved scalp and connected to a portable device.
Zhongnan hospital
Wuhan, Hubei, China
Disease-free survival
the length of time after primary treatment for glioblastoma ends that the patient survives without any signs or symptoms of glioblastoma.
Time frame: 1 year
Overall survival
The length of time from the date of diagnosis to death from cancer
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.